Literature DB >> 12532415

Spontaneous activation and signaling by overexpressed epidermal growth factor receptors in glioblastoma cells.

Christopher Y Thomas1, Michael Chouinard, Michael Cox, Sarah Parsons, Melody Stallings-Mann, Roy Garcia, Richard Jove, Robert Wharen.   

Abstract

Overexpressed epidermal growth receptor factor receptors (EGFRs) are thought to contribute to the malignant phenotype of human glioblastomas (GBMs), but the mechanism is not well understood. We found that SKMG-3 cells, a rare GBM cell line that maintains EGFR gene amplification in vitro, produced high levels of EGFR protein. The cells also expressed the related receptors HER2/neu and HER4, but not HER3. Immunoblots and tryptic phosphopeptide maps showed that the SKMG-3 EGFRs were intact and functional and that a subset of these receptors were spontaneously autophosphorylated. EGF treatment stimulated phosphorylation of the EGFRs as well as the downstream effectors Erk, AKT1, stat3 and c-Cbl. Under minimal growth conditions, the unstimulated SKMG-3 cells contained constitutively phosphorylated Erk and AKTI but no detectable stat3 DNA-binding complexes. The EGFR kinase inhibitor PD158780 reduced the constitutive phosphorylation of the receptor and Erk but not that of AKT1. In contrast, inhibition of phosphatidylinositol-3-kinase (PI3K) blocked the constitutive phosphorylation of Erk and AKT-1 but not the EGFR. We conclude that the SKMG-3 cells represent the subset of GBMs with amplified EGFR genes that overexpress intact receptors. The results also suggest that in some GBMs, signals from overexpressed EGFRs contribute to the constitutive phosphorylation of Erk, but these signals may not required for the constitutive activation of PI3K or AKT1. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12532415     DOI: 10.1002/ijc.10880

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  21 in total

1.  A unique model system for tumor progression in GBM comprising two developed human neuro-epithelial cell lines with differential transforming potential and coexpressing neuronal and glial markers.

Authors:  Anjali Shiras; Arti Bhosale; Varsha Shepal; Ravi Shukla; V S Baburao; K Prabhakara; Padma Shastry
Journal:  Neoplasia       Date:  2003 Nov-Dec       Impact factor: 5.715

2.  Effect of EGF-receptor tyrosine kinase inhibitor on Rab5 function during endocytosis.

Authors:  Ivan Jozic; Samar C Saliba; M Alejandro Barbieri
Journal:  Arch Biochem Biophys       Date:  2012-06-05       Impact factor: 4.013

3.  Increasing of HER2 membranar density in human glioblastoma U251MG cell line established in a new nude mice model.

Authors:  Jean-François Mineo; Anne Bordron; Isabelle Quintin-Roué; Quintin-Roué Isabelle; Claude-Alain Maurage; Virginie Buhé; Buhé Virginie; Séverine Loisel; Loisel Séverine; François Dubois; Serge Blond; Christian Berthou
Journal:  J Neurooncol       Date:  2006-02       Impact factor: 4.130

4.  NPAS3 demonstrates features of a tumor suppressive role in driving the progression of Astrocytomas.

Authors:  Frederico Moreira; Tim-Rasmus Kiehl; Kelvin So; Norbert F Ajeawung; Carmelita Honculada; Peter Gould; Russell O Pieper; Deepak Kamnasaran
Journal:  Am J Pathol       Date:  2011-05-19       Impact factor: 4.307

5.  An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop regulates the activation of EGFRvIII.

Authors:  L Li; S Chakraborty; C-R Yang; K J Hatanpaa; D J Cipher; V T Puliyappadamba; A Rehman; A J Jiwani; B Mickey; C Madden; J Raisanen; S Burma; D Saha; Z Wang; S C Pingle; S Kesari; D A Boothman; A A Habib
Journal:  Oncogene       Date:  2013-09-30       Impact factor: 9.867

6.  Progranulin Deficiency Reduces CDK4/6/pRb Activation and Survival of Human Neuroblastoma SH-SY5Y Cells.

Authors:  Ana de la Encarnación; Carolina Alquézar; Noemí Esteras; Ángeles Martín-Requero
Journal:  Mol Neurobiol       Date:  2014-11-07       Impact factor: 5.590

7.  Differential distribution of erbB receptors in human glioblastoma multiforme: expression of erbB3 in CD133-positive putative cancer stem cells.

Authors:  Véronique Duhem-Tonnelle; Ivan Bièche; Sophie Vacher; Anne Loyens; Claude-Alain Maurage; Francis Collier; Marc Baroncini; Serge Blond; Vincent Prevot; Ariane Sharif
Journal:  J Neuropathol Exp Neurol       Date:  2010-06       Impact factor: 3.685

8.  Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma.

Authors:  Jean-François Mineo; Anne Bordron; Marc Baroncini; Claude-Alain Maurage; Carole Ramirez; Rose-Mary Siminski; Christian Berthou; Phong Dam Hieu
Journal:  J Neurooncol       Date:  2007-06-15       Impact factor: 4.130

Review 9.  HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.

Authors:  Jeffrey J Raizer
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

10.  Recombinant humanised anti-HER2/neu antibody (Herceptin) induces cellular death of glioblastomas.

Authors:  J-F Mineo; A Bordron; I Quintin-Roué; S Loisel; K L Ster; V Buhé; N Lagarde; C Berthou
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.